Replies to post #349032 on Anavex Life Sciences Corp (AVXL)

[JWC3]

Are you kidding. Anavex results are proof enough for any credibility argument. Watch what the FDA concludes.

[XenaLives]

Non-sequitur argument...

... and another reason to ignore AF.

Acadia Pharmaceuticals (ACAD) - Get ACADIA Pharmaceuticals Inc. Report secured its first-ever U.S. drug approval on Friday. The drug, Nuplazid, is also the first medicine approved by the U.S. Food and Drug Administration to quell hallucinations and delusions often experienced with people with advanced Parkinson's disease.

Yet, investors are shrugging off Acadia's good news. On Monday, Acadia shares opened higher, sank 5% and the rebounded to close up 2%. Tuesday, Acadia is down over 7% to $30.62, likely due to an analyst downgrade.

A number of factors help explain the less-than-celebratory reaction to Nuplazid's approval.
.....

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

https://www.thestreet.com/investing/stocks/why-acadia-pharma-s-first-drug-approval-isn-t-moving-stock-higher-13555055

Current price $23.46:


https://www.marketwatch.com/investing/stock/acad

[Investor2014]

Yeah, and an ongoing class action case against them for allegedly making false and/or misleading statements in their NDA filing about their only approved drug.